NO20081863L - Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse - Google Patents

Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse

Info

Publication number
NO20081863L
NO20081863L NO20081863A NO20081863A NO20081863L NO 20081863 L NO20081863 L NO 20081863L NO 20081863 A NO20081863 A NO 20081863A NO 20081863 A NO20081863 A NO 20081863A NO 20081863 L NO20081863 L NO 20081863L
Authority
NO
Norway
Prior art keywords
compound
active vitamin
chemotherapy
gastrointestinal
prevention
Prior art date
Application number
NO20081863A
Other languages
English (en)
Norwegian (no)
Inventor
John G Curd
Bradford S Goodwin
Jeffrey L Cleland
Original Assignee
Novcea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novcea Inc filed Critical Novcea Inc
Publication of NO20081863L publication Critical patent/NO20081863L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20081863A 2005-09-26 2008-04-17 Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse NO20081863L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71998805P 2005-09-26 2005-09-26
PCT/US2006/037246 WO2007038428A2 (fr) 2005-09-26 2006-09-26 Prevention et traitement des troubles gastro-intestinaux et de la vessie lies a la chimiotherapie ou a la radio therapie a l'aide de composes actifs de vitamine d

Publications (1)

Publication Number Publication Date
NO20081863L true NO20081863L (no) 2008-06-04

Family

ID=37900359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081863A NO20081863L (no) 2005-09-26 2008-04-17 Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse

Country Status (10)

Country Link
US (1) US20090163453A1 (fr)
EP (1) EP1928471A2 (fr)
JP (1) JP2009513567A (fr)
KR (1) KR20080063790A (fr)
AU (1) AU2006294819A1 (fr)
BR (1) BRPI0616330A2 (fr)
CA (1) CA2622470A1 (fr)
IL (1) IL190067A0 (fr)
NO (1) NO20081863L (fr)
WO (1) WO2007038428A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d
WO2008097646A1 (fr) * 2007-02-09 2008-08-14 Schering Corporation Procédés pour traiter et/ou prévenir la mucosite
EP1972341A1 (fr) * 2007-03-23 2008-09-24 Novartis AG Compositions pharmaceutiques contenant un bisphosphonate et de la vitamine D
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
PL388252A1 (pl) * 2009-06-10 2010-12-20 Instytut Farmaceutyczny Terapia skojarzona raka jelita grubego
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
JP5686841B2 (ja) * 2013-04-26 2015-03-18 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
AU2014349663A1 (en) 2013-11-17 2016-06-02 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CN104758300A (zh) * 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol
KR102381242B1 (ko) 2016-01-13 2022-03-31 엘지전자 주식회사 냉장고
CN111450104A (zh) * 2020-05-22 2020-07-28 中国人民解放军第二军医大学 维生素d在防治辐射所致肠损伤中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204615B1 (en) * 1997-02-21 2001-03-20 Intelilite, L.L.C. Intelligent outdoor lighting control system
US6891838B1 (en) * 1998-06-22 2005-05-10 Statsignal Ipc, Llc System and method for monitoring and controlling residential devices
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU2002341566A1 (en) * 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
AU2004265238A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin D compounds in combination with other treatments
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2566346A1 (fr) * 2004-05-10 2005-11-24 Novacea, Inc. Prevention contre la restenose arterielle a l'aide de composes actifs de vitamine d
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AU2006204091A1 (en) * 2005-01-05 2006-07-13 Tomasz M. Beer Prevention of thrombotic disorders with active vitamin D compounds or mimics thereof

Also Published As

Publication number Publication date
KR20080063790A (ko) 2008-07-07
EP1928471A2 (fr) 2008-06-11
IL190067A0 (en) 2008-12-29
WO2007038428A2 (fr) 2007-04-05
JP2009513567A (ja) 2009-04-02
AU2006294819A1 (en) 2007-04-05
WO2007038428A3 (fr) 2009-09-11
US20090163453A1 (en) 2009-06-25
CA2622470A1 (fr) 2007-04-05
BRPI0616330A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
NO20081863L (no) Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse
JP2015519329A5 (fr)
Zhou et al. PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway
NO20070702L (no) Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
NO20070597L (no) Medikamtenter for a behandle kronisk respiratorisk sykdom.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
Kwon et al. Modulatory effects of acupuncture on murine depression-like behavior following chronic systemic inflammation
JP2017510607A5 (fr)
NO20080244L (no) Doseringsstyring for prasugrel
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
WO2007079195A3 (fr) Formes posologiques de gabapentine a retention gastrique et leurs procedes d'utilisation
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
JP2016505050A5 (fr)
WO2009003694A3 (fr) Procédé de traitement de maladies liées à un dysfonctionnement mitochondrial
JP2019529569A5 (fr)
WO2017142871A8 (fr) Procédés comprenant un dosage intermittent et fixe de cediranib
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
JP2017515858A5 (fr)
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application